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MicroRNAs (miRNAs) are small noncod-
ing RNAs of approximately 22 nucleotides 
in length that regulate gene expression 
post-transcriptionally. These small RNAs 
are fundamental regulators of several cel-
lular processes, such as differentiation, 
development, apoptosis, proliferation, cell 
cycle regulation and metabolism, through 
the binding to 3' untranslated regions, 
coding sequence or 5' untranslated regions 
of target messenger RNAs (mRNAs), pre-
venting their translation or causing their 
degradation.1 A modest change in only 
one miRNA will affect multiple mRNA 
targets; consequently, the deregulation 
of miRNAs has important consequences 
to the cellular homeostatic stability, and 
aberrant miRNAs expression patterns have 
been described in several types of cancer.2 
Recently, miRNAs have been implicated 
in the metastatic process of several tumors 
such as human breast and colorectal 
cancers3 and, as reported this issue of 
Cancer Biology & Therapy by Guo et al. 
in neuroblastoma.4 These are extracranial 
solid tumors, arising from neural crest 
cells, that are most common in infants 
and children; metastasis, the main cause 
of death, is present at the time of diag-
nosis in approximately 60% of patients.5 
Metastatic disease may cause bone pain, 
bone marrow suppression and weight 
loss, but some patients do not present 
symptoms.6 Therefore, the study by Guo 
et al. is important for the identifica-
tion of specific miRNAs responsible for 
metastasis not only to better understand 
the molecular behavior of theses tumors 
but also to identify markers of early 
diagnosis/prognosis, and in the future, 
possible new therapeutic targets.
Using a heterotopic transplant mouse 
model of neuroblastoma and a microRNA 
microarray analysis approach, Guo et 
al. identified 54 miRNAs differentially 
expressed between primary and metastatic 
neuroblastoma tumors.4 Three of the 
top ten downregulated miRNAs in this 
study, namely miR-7, miR-338-3p and 
the let-7 family, have an anti-metastatic 
role in other tumors types.7 Specifically, in 
breast cancer, Reddy et al. described that 
endogenous miR-7 expression is positively 
regulated by the homeodomain transcrip-
tion factor HoxD10, a gene that has been 
linked with the invasive and metastatic 
potential in human breast cancer cells. 
In this breast cancer cell line, the authors 
showed that miR-7 introduction suppresses 
motility, invasiveness, anchorage inde-
pendence and tumorigenesis.8 Regarding 
miR-338-3p, it has been suggested that 
this microRNA contributes to the forma-
tion of basolateral polarity in epithelial 
cells, which can be important for metas-
tasis prevention.9 Concerning the let-7 
family, several studies demonstrate that it 
can inhibit tumorigenesis and metastasis 
as it targets important oncogenes such as 
RAS, MYC and HMGA2. Interestingly, 
MYC and let-7 are involved in a feed-
back loop since MYC can be a target of 
let-7 and at the same time can control its 
expression. In breast tumor cells, Dangi-
Garimella et al. demonstrate that RKIP 
represses metastasis, in part, through a 
signalling cascade that involves the inhibi-
tion of MAPK, MYC and LIN28, leading 
MicroRNAs and metastases
The neuroblastoma link
Maria I. Almeida,1,2 Rui M. Reis2 and George A. Calin1,*
1Department of Experimental Therapeutics and the Center for RNA Interference and Non-Coding RNAs; The University of Texas M.D. Anderson Cancer 
Center; Houston, TX USA; 2Life and Health Sciences Research Institute (ICVS); School of Health Sciences; University of Minho; Braga Portugal
Commentary to: Guo J,  Dong Q, Fang Z, Chen X, 
Lu H, Wang K, et al. Identification of miRNAs that 
are associated with tumor metastasis in neuro-
blastoma. Cancer Biol Ther 2010; This issue.
454 Cancer Biology & Therapy Volume 9 Issue 6
the neuroblastoma cell surface activate 
a CASP8-dependent checkpoint and 
block cell invasion into an inappropriate 
microenvironment.11 This mechanism 
is inactive in the absence of CASP8.11,12 
Interestingly, integrins are also predicted 
to be a target of miR-29a/b, which is over-
expressed in metastatic versus primary 
neuroblastoma.4 In addition to CASP8 
deletion and methylation,12 it is tempt-
ing to speculate that another mechanism 
by which CASP8 is downregulated in 
metastatic neuroblastoma is through 
miR-29a/b overexpression. However, it 
is imperative to validate this hypothesis 
through functional studies.
It will be important in future studies 
to functionally validate the interference 
between the other miRNAs that were dif-
ferently expressed (primary versus meta-
static NB) in the Guo et al. study and 
the predicted targets. In humans, neuro-
blastoma can metastasize to bone, bone 
marrow, lung, liver and/or non-contigous 
lymph nodes.13 It will be also interesting to 
analyse differences at the microRNA level 
between the different metastatic sites.
In conclusion, the identification of dif-
ferentially expressed microRNA in the 
metastasis of neuroblastoma is an impor-
tant step towards the understanding of the 
metastatic process in this disease.
to the induction of let-7 and the conse-
quent downregulation of its targets.10
In the present reported study, Guo et 
al. also identified several miRNAs whose 
association with metastases was not pre-
viously described. In futures studies, it 
will be important to further analyse those 
miRNAs with the purpose of understand-
ing their functional role in metastisa-
tion. In addition to the identification of 
miRNAs involved in the neuroblastoma 
metastatic process, and using computer-
aided algorithms, Guo et al. suggest 
potential mRNA targets that can be regu-
lated by those miRNAs. Interestingly, 
some of those targets have been described 
as deregulated in neuroblastoma.4 For 
example, according to Guo et al. miR-29-
a/b is overexpressed in metastatic neuro-
blastoma and one of the predicted targets 
of this microRNA is CASP8. The absence 
of this apoptosis-mediated protein has 
been implicated in neuroblastoma metas-
tasis in vivo. In chick embryos, Stupack et 
al. detected lung and bone marrow neu-
roblastoma metastases mostly in embryos 
bearing tumors deficient in CASP8 when 
compared to CAPS8-positive tumors. 
Furthermore, reconstitution of CASP8 
expression significantly suppressed 
metastasis.11 The authors propose that 
unligated or antagonised integrins on 
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